🧠 mets (4-10) ➡️ SRS vs WBRT 🔺All histologies ( ❌SCLC ) 🔺NO significant differences for OS and iPFS 🔺 No G3 toxicities in the SRS-cohort giuseppe Minniti Stefanie Corradini 🌟 OncoAlert @RadiotherapyOn1 radoncreview_org thegreenjournal.com/article/S0167-…

📌 ADT ➕ RT in cN1M0 #Prostate #cancer ✔️⤴️ disease control ✔️⤴️overall survival ➡️ independent of other tumour and treatment factors Prof Ananya💙 @achoud72.bsky.social Kamal Thippu MD FRCR Priyamvada Maitre @RadiotherapyOn1 OncoAlert European Association of Urology (EAU) UroToday.com Uromigos thegreenjournal.com/article/S0167-…

Excited to share that our prostate SBRT guide is now online (pre-proof) at PRO. This Radiosurgery Society endorsed guide discusses many practical/controversial aspect of care when delivering prostate SBRT illustrated by two challenging cases. practicalradonc.org/article/S1879-…

🔗#Prostate #cancer OS predictive factors after MDT: 🔹3D total tumour volume 🔹site of oligometastases 🔷bitly.ws/UUjj marta scorsetti Ciro Franzese Clinical Oncology OncoAlert UroToday.com European Association of Urology (EAU) Uromigos RadOnc Tables radoncreview_org youngAIRO AIRO Radioterapia_Oncologica

Elective Nodal Irradiation: Old Game, New SPORT redjournal.org/article/S0360-… Danny Vesprini takes a sporty look at the old game! Read on..IJROBP - The Red Journal

My #AIRO2023 youngAIRO AIRO Radioterapia_Oncologica #RadOnc

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotro… pubmed.ncbi.nlm.nih.gov/37796473/

🔎 MDT in #Prostate #cancer ✅favourable PFS ✅excellent LC ✅low toxicity profile ✅ delay ⏱️ ADT in oligorecurrent hormone-sensitive pts Piet Ost Thomas Zilli Giorgio Gandaglia European Urology UroToday.com OncoAlert RadOnc Tables sciencedirect.com/science/articl…

🔚 of my #RadOnc residency at Università degli Studi di Milano-Bicocca Very grateful to my family, mentors, faculty, co-residents and staff who helped me in this training course❗️

💥 Proud to present my first manuscript on salvage SBRT for PCa late toxicity and QoL, now in Clinical & Translational Radiation Oncology 💥 Check out the POPART 🇮🇹multicentric trial ctro.science/article/S2405-… Stefano Arcangeli Ciro Franzese Valeria Faccenda marta scorsetti Denis Panizza Maria Belmonte Raffaella Lucchini

I’m excited to start a new experience… #RadOnc at Humanitas Milano ‼️ Thanks to Prof marta scorsetti for this opportunity!

Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity ⁦Vérane Achard⁩ ⁦Vedang Murthy⁩ ⁦Priyamvada Maitre⁩ ctro.science/article/S2405-…

🎬 our paper on 1️⃣-shot⚡️RT for UIR and HR PCa is finally out on IJROBP - The Red Journal 👏kudos to the authors for the team effort! #ABRUPT Chiara Chissotti Federica Ferrario Raffaella Lucchini Maria Belmonte Riccardo Ray Colciago Valeria Faccenda Denis Panizza redjournal.org/article/S0360-…

STRILL: Phase I trial of stereotactic reirradiation of lung metastases previously treated with SBRT ..unsurprisingly, 50/5# reirradiation yields higher local control without notable toxicity. Nice collaboration with Humanitas Milano marta scorsetti mdpi.com/2079-9721/12/7…

Our latest research on oligorecurrent kidney cancer patients treated with upfront SBRT. Key predictive factors that contribute to long-term disease control, offering valuable insights for personalized treatment strategies and prospective trials. lnkd.in/eJEhgk_6

Joining forces against kidney cancer! Published a new international multicenter study on SBRT for renal cell carcinoma SBRT is a valuable option with: ✅ 96% local control at 5 years ✅ Good preservation of renal function ✅ Acceptable toxicity profile with only 1% of G ≥3

Today in Castelfranco for the lII edition of Advanced Uro-Oncology Days. My presentation about #MDT in oligoM+ #urothelialcancer. Many compliments to Matteo Sepulcri , Marco Maruzzo, and to scientific committee of the event!

#ESTRO25 You’ve been amazing ✨ ~2️⃣nd year in a row on stage with the #POPART trial ~🌍 Global connections with inspiring minds ~🏅 Top 5% abstract — couldn’t be prouder! 🙏🏼 Infinite thanks to my mentor & colleagues. Here’s to science, passion&teamwork! #RadOnc #prostatecancer

A week at DCPT proton therapy ☢️🇩🇰: a great experience. Thanks to the prof Morten Høyer and all the staff for their hospitality! #protontherapy

So proud to share mid-term results of our POPART trial on prostate bed SBRT — core of my thesis and a project I deeply believe in ✨ Alongside #SCIMITAR & #SHORTER, another step towards the 5fx revolution! 💥 Forever🙏🏼Stefano Arcangeli 50days free access⬇️ authors.elsevier.com/c/1lYbQcA0-MUS1